Research & Development Highlights Presented encouraging initial data from first four dosing cohorts of ongoing Phase 1/2a trial of MP0533 for patients with relapsed/refractory AML and AML/MDS at the ASH Annual Meeting, reporting an acceptable safety profile and initial anti-tumor activity

Tetra-specific T-cell engager MP0533 for patients with r/r AML and AML/MDS on track to deliver expanded clinical phase 1/2a data in H1 2024 Progress of Radio-DARPin Therapy (RDT) platform: Improved tumor to kidney uptake ratio enables expansion of RDT pipeline; first data on DLL3 as lead candidate;

Collaboration leverages lead-based ( 212 Pb) alpha emitter expertise and supply of Orano Med with Molecular Partners’ leadership in DARPins for tumor-targeted delivery of radioactive payloads Co-Development agreement covers multiple oncology targets, including DLL3 Companies anticipate

Initial antitumor activity observed in early MP0533 dose-escalation cohorts, with a previously undisclosed complete response (CR) observed in dose range four, in addition to the previously reported responder in dose range three MP0533 monotherapy continues to demonstrate an acceptable safety

MP0533 shows acceptable safety profile in first three dose cohorts (5 patients total, data cut-off July 20); reported adverse reactions are of Grade 1/2 and no dose-limiting toxicity observed to date Emerging evidence of antitumor activity observed in dose cohort three, with one responder noted

MP0317 Phase 1 dose escalation recruitment completed in patients with advanced solid tumors; updated clinical results to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2023 MP0533 Phase 1/2a recruitment in r/r AML patients proceeding as planned with

Phase 1/2a clinical trial of tetraspecific T cell engager candidate MP0533 initiated in patients with relapsed/refractory AML and MDS/AML; dosing ongoing in the 4th dose cohort; initial data expected in Q4 2023 Positive MP0317 data of ongoing Phase 1 clinical trial presented at ASCO confirm

MP0317 demonstrates tumor-localized CD40 activation in tumor biopsies through target occupancy and immune cell activation MP0317 demonstrates a favorable safety profile across Q3W and Q1W regimens, including the highest dose tested, 10mg/kg (Q3W) Present data support planning of future combination

MP0533: Phase 1 trial of MP0533 for AML ongoing; initial recruitment is progressing well, and site expansion is ongoing; initial clinical results on track for Q4 2023 MP0317: Highest dose cohort (Q3W, 10mg/kg) now enrolling; clinical update at ASCO Radio DARPin Therapy (RDT): Presented preclinical

Research & Development Highlights: Initiated Phase 1 study of MP0533, a novel tri-specific T-cell engager for the treatment of acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS) Presented preclinical data supporting the unique design and mechanism of MP0533 at the 64th